Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

被引:82
作者
Adi, Handoko [1 ]
Young, Paul M. [1 ]
Chan, Hak-Kim [1 ]
Agus, Helen [2 ]
Traini, Daniela [1 ]
机构
[1] Univ Sydney, Adv Drug Delivery Grp, Fac Pharm A15, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Sci G08, Sydney, NSW 2006, Australia
关键词
Mannitol; Ciprofloxacin; Dry powder inhaler (DPI); Cystic fibrosis; Antibiotics; Mucolytics; RECOMBINANT HUMAN DNASE; HIGH-DOSE IBUPROFEN; PSEUDOMONAS-AERUGINOSA; N-ACETYLCYSTEINE; LUNG-FUNCTION; MUCUS CLEARANCE; INHALATION; ANTIBIOTICS; SAFETY; INFECTION;
D O I
10.1016/j.ejps.2010.03.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to assess the potential of delivering a combination therapy, containing mannitol (a sugar alcohol with osmotic characteristics), and ciprofloxacin hydrochloride (an antibacterial fluoroquinolone), as a dry powder inhaler (DPI) formulation for inhalation. Single and combination powders were produced by spray drying ciprofloxacin and mannitol, from aqueous solution, at different ratios and under controlled conditions, as to obtain similar particle size distributions. Each formulation was characterised using laser diffraction, scanning electron microscopy, differential scanning calorimetry, dynamic vapour sorption, X-ray powder diffraction, and colloidal force microscopy. The in vitro aerosol performance of each formulation was studied using an Aerolizer (R) DPI device and a multi-stage liquid impinger (analysed using high performance liquid chromatography). In addition, a disk diffusion test was performed to assess the in vitro antimicrobial activity of each formulation and starting materials. All formulations had similar particle size distributions, however, the morphology, thermal properties and moisture sorption was dependent on the relative percentages of each component. In general, the combination formulation containing 50% (w/w) mannitol appeared to have the best aerosol performance, good stability and lowest particle cohesion (as measured by colloid probe microscopy). Furthermore, of the formulations tested, mannitol did not appear to alter the effectiveness of the ciprofloxacin antimicrobial activity to Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes. The combination of co-spray-dried mannitol and ciprofloxacin from a DPI is an attractive approach to promote mucous clearance in the respiratory tract while simultaneously treating local chronic infection, such as chronic obstructive pulmonary disease and cystic fibrosis. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 46 条
  • [11] Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease
    Zhong, Nanshan
    Zheng, Jinping
    Wen, Fuqiang
    Yang, Lan
    Chen, Ping
    Xiu, Qingyu
    Yao, Wanzhen
    Sun, Tieying
    Zhao, Ziwen
    Shen, Huahao
    Shi, Yi
    Lin, Jiangtao
    Li, Qiang
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 257 - 265
  • [12] Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis
    Atanasova, Kalina R.
    Reznikov, Leah R.
    [J]. RESPIRATORY RESEARCH, 2018, 19
  • [13] Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis
    Kalina R. Atanasova
    Leah R. Reznikov
    [J]. Respiratory Research, 19
  • [14] Cystic Fibrosis Transmembrane Conductance Regulator Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
    Cantin, Andre M.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 : S150 - S155
  • [15] Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea
    Moon, Ji-Yong
    Kim, Sang Hyuk
    Kim, Youlim
    Lee, Hyun
    Rhee, Chin Kook
    Ra, Seung Won
    Lee, Chang Youl
    Park, Joo Hun
    Park, Yong Bum
    Yoo, Kwang Ha
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2024, 85
  • [16] Cospray-Dried Unfractionated Heparin With L-Leucine as a Dry Powder Inhaler Mucolytic for Cystic Fibrosis Therapy
    Shur, Jagdeep
    Nevell, Thomas G.
    Ewen, Richard J.
    Price, Robert
    Smith, Andrew
    Barbu, Eugen
    Conway, Joy H.
    Carroll, Mary P.
    Shute, Janis K.
    Smith, James R.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (11) : 4857 - 4868
  • [17] Comparison between spray drying and freeze drying techniques for the preparation of microparticles for delivery via a dry powder inhaler to treat cystic fibrosis
    Kabra, Vinayak
    Lahoti, Swaroop
    [J]. JOURNAL OF RESEARCH IN PHARMACY, 2023, 27 (06): : 2443 - 2451
  • [18] Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum
    David J Serisier
    Mary P Carroll
    Janis K Shute
    Simon A Young
    [J]. Respiratory Research, 10
  • [19] Noninvasive ventilation in chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis
    Wedzicha, JA
    Muir, JF
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (03) : 777 - 784
  • [20] Co-spray-dried poly-L-lysine with L-leucine as dry powder inhalations for the treatment of pulmonary infection: Moisture-resistance and desirable aerosolization performance
    Zhang, Xuejuan
    Zhou, Yue
    Wang, Guanlin
    Zhao, Ziyu
    Jiang, Zhongxiang
    Cui, Yingtong
    Yue, Xiao
    Huang, Zhengwei
    Huang, Ying
    Pan, Xin
    Wu, Chuanbin
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 624